Shanghai:688235

Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene

Retrieved on: 
Monday, April 25, 2022
Drug development, CEO, BTK, Bispecific monoclonal antibody, Monoclonal antibody, Twitter, Research, NASDAQ, Patient, Efficiency, PARP, Amblyomma integrum, Technology, Proteolysis, Tislelizumab, Chimera, CDAC, Mouse, SSE, ADC, Senior, Therapy, Cancer, Vaccine, EU, BeiGene

BEIJING, April 25, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") reached an agreement with BeiGene (Beijing) Co., Ltd. ("BeiGene") (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen's fully human antibody RenMab/RenLitemice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of antibody drugs.

Key Points: 
  • BEIJING, April 25, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") reached an agreement with BeiGene (Beijing) Co., Ltd. ("BeiGene") (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen's fully human antibody RenMab/RenLitemice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of antibody drugs.
  • RenMaband RenLitemice, which have proprietary intellectual property rights, were developed by Biocytogen over the course of 5 years using size-unlimited, precise chromosome engineering technology.
  • BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide.
  • Dr. Lai Wang, Senior Vice President and Global Head of R&D of BeiGene, said, "BeiGene has always been focused on developing differentiated innovative drugs and the application of innovative technologies.

Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene

Retrieved on: 
Monday, April 25, 2022
Drug development, CEO, BTK, Bispecific monoclonal antibody, Monoclonal antibody, Twitter, Research, NASDAQ, Patient, Efficiency, PARP, Amblyomma integrum, Technology, Proteolysis, Tislelizumab, Chimera, CDAC, Mouse, Multimedia, SSE, ADC, Senior, View, Therapy, Cancer, Vaccine, EU, BeiGene

BEIJING, April 25, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") reached an agreement with BeiGene (Beijing) Co., Ltd. ("BeiGene") (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen's fully human antibody RenMab/RenLitemice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of antibody drugs.

Key Points: 
  • BEIJING, April 25, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") reached an agreement with BeiGene (Beijing) Co., Ltd. ("BeiGene") (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen's fully human antibody RenMab/RenLitemice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of antibody drugs.
  • RenMaband RenLitemice, which have proprietary intellectual property rights, were developed by Biocytogen over the course of 5 years using size-unlimited, precise chromosome engineering technology.
  • BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide.
  • Dr. Lai Wang, Senior Vice President and Global Head of R&D of BeiGene, said, "BeiGene has always been focused on developing differentiated innovative drugs and the application of innovative technologies.